AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 10811493 — intervention group
Group type: COMPARATOR
Intervention: Observation and chemotherapy at progression (Control group, n = 81)
Number of subjects: 162
Study 10811493 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups pooled for analysis of prognostic factors
Number of subjects: 162
Study 8697160 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg lisinopril
Number of subjects: 19
Study 8697160 — intervention group
Group type: COMPARATOR
Intervention: 5 mg lisinopril
Number of subjects: 19
Study 1997305 — intervention group
Group type: EXPERIMENTAL
Intervention: Ionic contrast medium (meglumine diatrizoate, Urografin 76%)
Number of subjects: 1153
Study 1997305 — intervention group
Group type: COMPARATOR
Intervention: Nonionic contrast medium (iopromide, Ultravist ‐370)
Number of subjects: 1153
Study 6354600 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg chlormezanone
Number of subjects: 31
Study 6354600 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg chlormezanone
Number of subjects: 31
Study 6354600 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study 6354600 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlormezanone (both doses)
Number of subjects: 31
Study 29775246 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol 400 mg (therapeutic dose) on days 1-3, tramadol 100 mg and moxifloxacin-matched placebo on day 4, placebo on all 4 days
Number of subjects: 68
Study 29775246 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol 600 mg (supratherapeutic dose) on days 1-3, tramadol 150 mg and moxifloxacin-matched placebo on day 4
Number of subjects: 68
Study 29775246 — intervention group
Group type: COMPARATOR
Intervention: Placebo on days 1-4 and moxifloxacin-matched placebo on day 4
Number of subjects: 68
Study 29775246 — intervention group
Group type: COMPARATOR
Intervention: Placebo on days 1-4 and moxifloxacin 400 mg on day 4
Number of subjects: 68
Study 28799171 — intervention group
Group type: EXPERIMENTAL
Intervention: Denture group
Number of subjects: 0
Study 28799171 — intervention group
Group type: COMPARATOR
Intervention: No-denture group
Number of subjects: 0
Study 28799171 — intervention group
Group type: EXPERIMENTAL
Intervention: Posterior reduced mandibular dental arches
Number of subjects: 0
Study 26337213 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyaluronidase (1500 IU)
Number of subjects: 45
Study 26337213 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (8 mg)
Number of subjects: 45
Study 26337213 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of dexamethasone (4 mg) and hyaluronidase (750 IU)
Number of subjects: 45
Study 23364294 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryotherapy (ice application)
Number of subjects: 33
Study 23364294 — intervention group
Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 33
Study 21300635 — intervention group
Group type: EXPERIMENTAL
Intervention: Onabotulinum toxin A
Number of subjects: 28
Study 21300635 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 19618383 — intervention group
Group type: EXPERIMENTAL
Intervention: Trauma-related questionnaires
Number of subjects: 0
Study 19618383 — intervention group
Group type: COMPARATOR
Intervention: Nontrauma questionnaires
Number of subjects: 0
Study 17543174 — intervention group
Group type: EXPERIMENTAL
Intervention: Firebird sirolimus eluting stent
Number of subjects: 156
Study 17543174 — intervention group
Group type: COMPARATOR
Intervention: Bare metal stent (BMS)
Number of subjects: 156
Study 15084618 — intervention group
Group type: EXPERIMENTAL
Intervention: Calendula (Pommade au Calendula par Digestion; Boiron Ltd, Levallois‐Perret, France)
Number of subjects: 254
Study 15084618 — intervention group
Group type: COMPARATOR
Intervention: Trolamine (Biafine; Genmedix Ltd, France)
Number of subjects: 254
Study 15084618 — intervention group
Group type: EXPERIMENTAL
Intervention: Calendula
Number of subjects: 254
Study 15084618 — intervention group
Group type: COMPARATOR
Intervention: Trolamine
Number of subjects: 254
Study 11531947 — intervention group
Group type: EXPERIMENTAL
Intervention: recombinant human interferon-gamma (rhIFNgamma)
Number of subjects: 0
Study 11531947 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 0
Study 10193493 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI scanning
Number of subjects: 22
Study 10193493 — intervention group
Group type: COMPARATOR
Intervention: Bone scanning
Number of subjects: 22
Study 8092207 — intervention group
Group type: EXPERIMENTAL
Intervention: Estradiol-releasing silicone rubber vaginal ring (6.5 to 9.5 micrograms per 24 hours)
Number of subjects: 146
Study 8092207 — intervention group
Group type: COMPARATOR
Intervention: Ovesterin 0.5 mg estriol vaginal pessaries
Number of subjects: 146
Study 8092207 — intervention group
Group type: EXPERIMENTAL
Intervention: Estradiol-releasing silicone rubber vaginal ring
Number of subjects: 146
Study 8092207 — intervention group
Group type: COMPARATOR
Intervention: Estriol vaginal pessaries
Number of subjects: 146
Study 3385289 — intervention group
Group type: EXPERIMENTAL
Intervention: Stack splint
Number of subjects: 116
Study 3385289 — intervention group
Group type: COMPARATOR
Intervention: Abouna splint
Number of subjects: 116
Study 30669587 — intervention group
Group type: EXPERIMENTAL
Intervention: Quercetin (Q) 1000 mg/day
Number of subjects: 12
Study 30669587 — intervention group
Group type: EXPERIMENTAL
Intervention: Quercetin (Q)
Number of subjects: 12
Study 30669587 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 12
Study 28318926 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg/kg tranexamic acid followed by a continuous infusion of 1 mg/kg/h until the end of surgery
Number of subjects: 70
Study 28318926 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study 25937378 — intervention group
Group type: EXPERIMENTAL
Intervention: Dominant hand placement against the sternum
Number of subjects: 101
Study 25937378 — intervention group
Group type: COMPARATOR
Intervention: Nondominant hand placement against the sternum
Number of subjects: 101
Study 23648395 — intervention group
Group type: EXPERIMENTAL
Intervention: DASH diet intervention (8 group and 3 individual sessions over 3 months, followed by monthly phone consultations for another 3 months)
Number of subjects: 90
Study 23648395 — intervention group
Group type: COMPARATOR
Intervention: Usual care alone
Number of subjects: 90
Study 21278551 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based patient education
Number of subjects: 0
Study 21278551 — intervention group
Group type: COMPARATOR
Intervention: Face-to-face patient education
Number of subjects: 0
Study 21278551 — intervention group
Group type: EXPERIMENTAL
Intervention: Both education methods
Number of subjects: 0
Study 19624605 — intervention group
Group type: EXPERIMENTAL
Intervention: FFP-male
Number of subjects: 82
Study 19624605 — intervention group
Group type: COMPARATOR
Intervention: FFP-mixed
Number of subjects: 82
Study 16989830 — intervention group
Group type: EXPERIMENTAL
Intervention: Embryos derived from brown oocytes
Number of subjects: 0
Study 16989830 — intervention group
Group type: COMPARATOR
Intervention: Embryos derived from morphologically normal oocytes
Number of subjects: 0
Study 15062148 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib
Number of subjects: 149
Study 10799374 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 g AX-rich fiber
Number of subjects: 14
Study 10799374 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 g AX-rich fiber
Number of subjects: 14
Study 10799374 — intervention group
Group type: COMPARATOR
Intervention: AX-rich fiber bread
Number of subjects: 14
Study 8819606 — intervention group
Group type: EXPERIMENTAL
Intervention: Hand switch
Number of subjects: 72
Study 8819606 — intervention group
Group type: COMPARATOR
Intervention: Head switch
Number of subjects: 72
Study 1479562 — intervention group
Group type: EXPERIMENTAL
Intervention: Suction drainage
Number of subjects: 36
Study 1479562 — intervention group
Group type: COMPARATOR
Intervention: Passive tube drainage
Number of subjects: 36
Study 4080297 — intervention group
Group type: EXPERIMENTAL
Intervention: recombinant interferon-alpha 2C monotherapy
Number of subjects: 42
Study 4080297 — intervention group
Group type: COMPARATOR
Intervention: polychemotherapy with vincristine, melphalan, cyclophosphamide and prednisolone
Number of subjects: 42
Study 4080297 — intervention group
Group type: EXPERIMENTAL
Intervention: recombinant interferon-alpha 2C
Number of subjects: 42
Study 30953768 — intervention group
Group type: EXPERIMENTAL
Intervention: Endotoxin injection
Number of subjects: 22
Study 30953768 — intervention group
Group type: COMPARATOR
Intervention: Placebo injection
Number of subjects: 22
Study 30693884 — intervention group
Group type: EXPERIMENTAL
Intervention: Fletcher's applicator
Number of subjects: 50
Study 30693884 — intervention group
Group type: COMPARATOR
Intervention: Henschke applicator
Number of subjects: 50
Study 27005961 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish-oil supplementation (1800 mg of eicosapentaenoic acid and docosahexaenoic acid per day for 6 months)
Number of subjects: 23
Study 27005961 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish-oil supplementation
Number of subjects: 23
Study 27005961 — intervention group
Group type: COMPARATOR
Intervention: Baseline gene expression
Number of subjects: 23
Study 27005961 — intervention group
Group type: COMPARATOR
Intervention: Gene set enrichment analysis
Number of subjects: 23
Study 24766971 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine 1mg
Number of subjects: 32
Study 24766971 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine 2mg
Number of subjects: 32
Study 24766971 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 22805467 — intervention group
Group type: EXPERIMENTAL
Intervention: Peanut oral immunotherapy (OIT)
Number of subjects: 0
Study 22805467 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 21280458 — intervention group
Group type: EXPERIMENTAL
Intervention: True acupoint electrical stimulation (EG1)
Number of subjects: 99
Study 21280458 — intervention group
Group type: EXPERIMENTAL
Intervention: Sham acupoint stimulation (EG2)
Number of subjects: 99
Study 21280458 — intervention group
Group type: COMPARATOR
Intervention: No acupoint intervention (CG)
Number of subjects: 99
Study 18940119 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional Interferon 3 MIU, S/C, three times a week plus Ribavirin 800 to 1200 mg in divided doses daily for 12 weeks (Group-I, n=81)
Number of subjects: 227
Study 18940119 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional Interferon 3 MIU, S/C, three times a week plus Ribavirin 800 to 1200 mg in divided doses daily for 24 weeks (Group-II, n=81)
Number of subjects: 227
Study 18940119 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional Interferon 3 MIU, S/C, three times a week plus Ribavirin 800 to 1200 mg in divided doses daily for 24 weeks (Group-III, n=65)
Number of subjects: 227
Study 15857840 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluorouracil-based first-line chemotherapy in patients with advanced mucinous CRC
Number of subjects: 135
Study 15857840 — intervention group
Group type: COMPARATOR
Intervention: Fluorouracil-based first-line chemotherapy in patients with non-mucinous CRC (control group)
Number of subjects: 135
Study 12551866 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine 30 to 60 mg/d
Number of subjects: 343
Study 12551866 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine and cerivastatin combination
Number of subjects: 343
Study 12551866 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerivastatin 0.4 mg/d
Number of subjects: 343
Study 12551866 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 343
Study 9871860 — intervention group
Group type: EXPERIMENTAL
Intervention: Unoprostone isopropyl 0.12% twice daily
Number of subjects: 36
Study 9871860 — intervention group
Group type: COMPARATOR
Intervention: Timolol maleate 0.5% twice daily
Number of subjects: 36
Study 9871860 — intervention group
Group type: EXPERIMENTAL
Intervention: Unoprostone isopropyl 0.12% three times daily
Number of subjects: 36
Study 7847298 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-alpha (6 million units three times/wk for 6 months) plus ursodeoxycholic acid (10 mg/kg/day for 9 months)
Number of subjects: 40
Study 7847298 — intervention group
Group type: COMPARATOR
Intervention: Interferon-alpha (6 million units three times/wk for 6 months) alone
Number of subjects: 40
Study 7847298 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-alpha + UDCA
Number of subjects: 40
Study 7847298 — intervention group
Group type: COMPARATOR
Intervention: Interferon-alpha alone
Number of subjects: 40
Study 2140970 — intervention group
Group type: EXPERIMENTAL
Intervention: 1,500 mg of acetyl-L-carnitine for 45 days
Number of subjects: 469
Study 2140970 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 30 days
Number of subjects: 469
Study 354397 — intervention group
Group type: EXPERIMENTAL
Intervention: Timolol ophthalmic solution
Number of subjects: 0
Study 354397 — intervention group
Group type: COMPARATOR
Intervention: Pilocarpine
Number of subjects: 0
Study 30986536 — intervention group
Group type: EXPERIMENTAL
Intervention: MINIMAL or INTENSE intervention components delivered face-to-face or via telephone by Patient Navigators (PN)
Number of subjects: 254
Study 30986536 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of pharmacologic support for abstinence (NRT)
Number of subjects: 254
Study 30986536 — intervention group
Group type: COMPARATOR
Intervention: No specific intervention groups
Number of subjects: 254
Study 28474783 — intervention group
Group type: EXPERIMENTAL
Intervention: Peri-implant probing
Number of subjects: 80
Study 28474783 — intervention group
Group type: COMPARATOR
Intervention: Periodontal probing
Number of subjects: 80
Study 26397087 — intervention group
Group type: EXPERIMENTAL
Intervention: Tethered-kicking intervention
Number of subjects: 16
Study 22311104 — intervention group
Group type: EXPERIMENTAL
Intervention: Avoidant attachment and emotion-focused coping
Number of subjects: 94
Study 22311104 — intervention group
Group type: EXPERIMENTAL
Intervention: Avoidant and insecure attachment styles
Number of subjects: 94
Study 21987709 — intervention group
Group type: EXPERIMENTAL
Intervention: School-based influenza vaccination intervention
Number of subjects: 370
Study 21987709 — intervention group
Group type: EXPERIMENTAL
Intervention: Provider-based influenza vaccination intervention
Number of subjects: 370
Study 21987709 — intervention group
Group type: COMPARATOR
Intervention: Standard-of-care condition
Number of subjects: 370
Study 17932967 — intervention group
Group type: EXPERIMENTAL
Intervention: Active diet (highly restricted diet based on spelt bread and red meat)
Number of subjects: 18
Study 17932967 — intervention group
Group type: COMPARATOR
Intervention: Control diet (low-fiber, low-fat, high-carbohydrate)
Number of subjects: 18
Study 17932967 — intervention group
Group type: EXPERIMENTAL
Intervention: Active diet
Number of subjects: 18
Study 17932967 — intervention group
Group type: COMPARATOR
Intervention: Control diet
Number of subjects: 18
Study 17932967 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Active and Control)
Number of subjects: 18
Study 16931685 — intervention group
Group type: EXPERIMENTAL
Intervention: Capsicum plaster (PAS) at Zusanli acupoints
Number of subjects: 90
Study 16931685 — intervention group
Group type: COMPARATOR
Intervention: Placebo tape at Zusanli acupoints
Number of subjects: 90
Study 16931685 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment (PAS at nonacupoints on shoulders)
Number of subjects: 90
Study 12897277 — intervention group
Group type: EXPERIMENTAL
Intervention: 21% O2
Number of subjects: 591
Study 12897277 — intervention group
Group type: COMPARATOR
Intervention: 100% O2
Number of subjects: 591
Study 11167470 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane 0.5 MAC supplemented with remifentanil (0.34 microg x kg(‐1) x min(‐1))
Number of subjects: 80
Study 11167470 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane 1.0 MAC supplemented with remifentanil (0.25 microg x kg(‐1) x min(‐1))
Number of subjects: 80
Study 11167470 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane 1.5 MAC supplemented with remifentanil (0.21 microg x kg(‐1) x min(‐1))
Number of subjects: 80
Study 11167470 — intervention group
Group type: COMPARATOR
Intervention: Sevoflurane only (control group)
Number of subjects: 80
Study 9551018 — intervention group
Group type: EXPERIMENTAL
Intervention: Public-private certified nurse-midwife program
Number of subjects: 0
Study 7904489 — intervention group
Group type: EXPERIMENTAL
Intervention: rHuGM‐CSF at a dose of 125 micrograms/m2/d by continuous intravenous infusion (group 2)
Number of subjects: 144
Study 7904489 — intervention group
Group type: EXPERIMENTAL
Intervention: rHuGM‐CSF at a dose of 250 micrograms/m2/d by continuous intravenous infusion (group 3)
Number of subjects: 144
Study 7904489 — intervention group
Group type: COMPARATOR
Intervention: PBC collected without mobilization (group 1)
Number of subjects: 144
Study 7904489 — intervention group
Group type: EXPERIMENTAL
Intervention: rHuGM‐CSF mobilization
Number of subjects: 144
Study 2756602 — intervention group
Group type: EXPERIMENTAL
Intervention: Arthroscopic procedure with partial meniscectomie
Number of subjects: 160
Study 2756602 — intervention group
Group type: COMPARATOR
Intervention: Arthrotomie and partial meniscectomie
Number of subjects: 160
Study 8062862 — intervention group
Group type: EXPERIMENTAL
Intervention: Active treatment with a pause of 2-3 months
Number of subjects: 40
Study 8062862 — intervention group
Group type: COMPARATOR
Intervention: Continuous active treatment without interruption
Number of subjects: 40
Study 380427 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous physostigmine (1.00 to 1.67 mg) administered at a rate of 0.5 mg/min every 4 min.
Number of subjects: 8
Study 380427 — intervention group
Group type: COMPARATOR
Intervention: Intravenous diazepam (0.102 to 0.238 mg/kg body weight)
Number of subjects: 8
Study 380427 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous physostigmine (1.00 to 1.67 mg)
Number of subjects: 8
Study 30592991 — intervention group
Group type: EXPERIMENTAL
Intervention: ipatasertib/mFOLFOX6
Number of subjects: 153
Study 30592991 — intervention group
Group type: COMPARATOR
Intervention: placebo/mFOLFOX6
Number of subjects: 153
Study 29696922 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture at Weishu (BL 21)
Number of subjects: 24
Study 29696922 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture at Zhongwan (CV 12)
Number of subjects: 24
Study 29696922 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture at combined Weishu (BL 21) and Zhongwan (CV 12)
Number of subjects: 24
Study 29696922 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture at combined front‐mu and back‐shu points
Number of subjects: 24
Study 29696922 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 24
Study 26582315 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided ilioinguinal/iliohypogastric nerve block (Group B)
Number of subjects: 40
Study 26582315 — intervention group
Group type: COMPARATOR
Intervention: Control group (no nerve block, Group NB)
Number of subjects: 40
Study 25426142 — intervention group
Group type: EXPERIMENTAL
Intervention: Chewing gum containing sorbitol
Number of subjects: 12
Study 25426142 — intervention group
Group type: EXPERIMENTAL
Intervention: Chewing gum containing xylitol
Number of subjects: 12
Study 25426142 — intervention group
Group type: EXPERIMENTAL
Intervention: Chewing gum containing a mixture of sorbitol and xylitol
Number of subjects: 12
Study 25426142 — intervention group
Group type: COMPARATOR
Intervention: Paraffin (control)
Number of subjects: 12
Study 22483445 — intervention group
Group type: EXPERIMENTAL
Intervention: Torus mandibularis bone chips combined with PRP gel
Number of subjects: 12
Study 22483445 — intervention group
Group type: COMPARATOR
Intervention: Torus mandibularis bone chips alone
Number of subjects: 12
Study 19347685 — intervention group
Group type: EXPERIMENTAL
Intervention: EGb 761(R) (240 mg per day)
Number of subjects: 96
Study 19347685 — intervention group
Group type: EXPERIMENTAL
Intervention: Donepezil (initially 5 mg, after 4 weeks 10 mg per day)
Number of subjects: 96
Study 19347685 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination treatment (EGb 761(R) and donepezil at the same doses)
Number of subjects: 96
Study 19347685 — intervention group
Group type: COMPARATOR
Intervention: Donepezil mono-therapy
Number of subjects: 96
Study 17497280 — intervention group
Group type: EXPERIMENTAL
Intervention: tirofiban+heparin
Number of subjects: 200
Study 17497280 — intervention group
Group type: COMPARATOR
Intervention: heparin
Number of subjects: 200
Study 14693783 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep sclerectomy with collagen implant (DSCI)
Number of subjects: 104
Study 14693783 — intervention group
Group type: COMPARATOR
Intervention: Deep sclerectomy (DS)
Number of subjects: 104
Study 11984209 — intervention group
Group type: EXPERIMENTAL
Intervention: DM-training
Number of subjects: 103
Study 11984209 — intervention group
Group type: EXPERIMENTAL
Intervention: DM-exposure
Number of subjects: 103
Study 11984209 — intervention group
Group type: COMPARATOR
Intervention: DM
Number of subjects: 103
Study 9818851 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg entacapone
Number of subjects: 171
Study 9818851 — intervention group
Group type: COMPARATOR
Intervention: Identical placebos
Number of subjects: 171
Study 7859897 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril 50 mg twice a day
Number of subjects: 22
Study 7859897 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 2760170 — intervention group
Group type: EXPERIMENTAL
Intervention: SMS 201-995 (100 micrograms)
Number of subjects: 5
Study 2760170 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5
Study 6161 — intervention group
Group type: EXPERIMENTAL
Intervention: Timolol 30 to 60 mg daily
Number of subjects: 20
Study 6161 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol 240 to 480 mg daily
Number of subjects: 20
Study 6161 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 31392559 — intervention group
Group type: EXPERIMENTAL
Intervention: CoQ10 100 mg/day for 2 months
Number of subjects: 54
Study 31392559 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study 27966269 — intervention group
Group type: COMPARATOR
Intervention: Blue-blocking intraocular lenses (IOL)
Number of subjects: 67